Pharmather is a specialty life sciences company focused on the research and development of psychedelic pharmaceuticals. The company was founded with a particular focus on repurposing psychedelic pharmaceuticals, such as ketamine and psilocybin, for FDA approval to treat disorders of the brain and nervous system. Pharmather’s goal is to advance the development of panaceAI™, their drug repurposing artificial intelligence platform, and advance their clinical product pipeline with ketamine and psilocybin in Parkinson’s disease, depression, traumatic brain injury and stroke.
Stock Performance
Pharmather Inc. News 45 articles
- PharmaTher Announces FDA Acceptance, As a Priority Original Abbreviated New Drug Application, for KETARX™ (Ketamine)
- PharmaTher Submits Priority Original Abbreviated New Drug Application for KETARX™ (Ketamine) to the FDA
- PharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics
- PharmaTher Initiates Filing of Abbreviated New Drug Application for KETARX™ (racemic ketamine) to the FDA
- PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S.
- PharmaTher Holdings Provides Corporate Update
- PharmaTher Holdings Submits Fast Track Application to FDA for KETARX™ (Ketamine) for the Treatment of Parkinson’s Disease
- PharmaTher Holdings Announces Update of Type C Meeting with the FDA for KETARX™ (Ketamine) in Parkinson’s Disease
- PharmaTher Submits FDA Meeting Package to Discuss 505(b)(2) Pathway for New Drug Application of KETARX™ (Ketamine) On-Body Pump System
- Revive Therapeutics Enters into Research Collaboration Agreement with PharmaTher for Development of MDMA Transdermal Patch
- PharmaTher Holdings Submits FDA Meeting Package to Discuss Phase 3 Program and Fast Track Designation for KETARX™ (Ketamine) in Parkinson’s Disease
- PharmaTher Holdings Submits for FDA Orphan Drug Designation for Ketamine to Treat Rett Syndrome
- PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
- PharmaTher Announces FDA Orphan Drug Designation Granted to Ketamine for Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
- PharmaTher Announces Poster Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at Neuroscience 2022 by the Society for Neuroscience
- PharmaTher Enters into Exclusive Option Agreement with Case Western Reserve University to Develop and Commercialize Ketamine for Rett Syndrome
- PharmaTher Holdings Announces Grant of U.S. Patent Covering Ketamine for Parkinson’s Disease
- PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022
- PharmaTher Announces Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine
- PharmaTher Announces Completion of IND-Enabling Pharmacokinetic and Tolerability Study with KETARX™ Ketamine Patch
- PharmaTher Announces Positive Results from Study For Ketamine Microneedle Patch
- PharmaTher To Develop and Commercialize Novel Wearable Ketamine Delivery Device in Collaboration with CCBIO
- PharmaTher Announces Grant of U.S. Patent on Formulation and Production Process of Ketamine and Ketamine Analogs
- PharmaTher Announces Publication of Research Data for Ketabet
- PharmaTher Enters Into Process Development Agreement With LTS LOHMANN for Ketamine Microneedle Patch
- PharmaTher Announces Positive Research Results for LSD Microneedle Patch
- PharmaTher Initiates Phase 2 Clinical Trial of Ketamine for the Treatment of Parkinson’s Disease
- PharmaTher Provides Product Pipeline Updates and Anticipated Milestones for Q4-2021 and 2022
- PharmaTher Provides Research and Development Update and Milestones for 2021
- PharmaTher and TSRL Enter into Co-Development Agreement For Microneedle Patch Delivery Technology for Psychedelics and Antivirals
- PharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease
- PharmaTher Announces Application with the FDA for Ketamine in the Treatment of Parkinson’s Disease
- PharmaTher Advancing Research for Delivery of Ketamine
- Depression Researcher Dr. Maurizio Fava Joins PharmaTher as Scientific and Clinical Advisor
- PharmaTher Announces Research Collaboration for Microneedle Delivery of Psychedelic Pharmaceuticals
- Revive Therapeutics Acquires Unique Psilocybin Assets
- PharmaTher Signs Exclusive Worldwide License Agreement for Patented Microneedle Delivery Technology to Deliver Ketamine
- PharmaTher Signs License Agreement for Patented Ketamine Treatment
- PharmaTher Approved to Trade on the OTCQB Venture Market
- PharmaTher Announces Application for OTCQB Listing
Showing the 40 most recent of 45 articles.